Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLDXNASDAQ:HSKANASDAQ:LNTHNASDAQ:MYGNNASDAQ:RIOT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$21.98-0.6%$20.37$14.40▼$47.00$1.46B1.13955,997 shs978,039 shsHSKAHeska$119.99$119.09$57.83▼$120.03$1.31B1.58241,932 shsN/ALNTHLantheus$79.21-0.5%$82.57$73.11▼$126.89$5.56B0.121.02 million shs329,518 shsMYGNMyriad Genetics$5.60-0.5%$5.09$3.81▼$29.30$516.19M1.911.26 million shs463,756 shsRIOTRiot Platforms$12.17-0.3%$9.31$6.19▼$15.87$4.35B4.5728.58 million shs27.63 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics-0.61%+3.80%+10.59%+39.26%-38.81%HSKAHeska0.00%0.00%0.00%0.00%0.00%LNTHLantheus-0.51%-1.89%+1.96%-12.88%-0.44%MYGNMyriad Genetics-0.53%+5.07%+14.75%-31.12%-77.56%RIOTRiot Platforms-0.25%+15.78%+34.76%+70.43%+27.16%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLDXCelldex Therapeutics3.1074 of 5 stars4.43.00.00.03.40.00.0HSKAHeskaN/AN/AN/AN/AN/AN/AN/AN/ALNTHLantheus4.2714 of 5 stars3.51.00.04.22.22.51.3MYGNMyriad Genetics4.2457 of 5 stars4.13.00.04.10.61.70.6RIOTRiot Platforms1.7244 of 5 stars3.52.00.00.01.70.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLDXCelldex Therapeutics 2.89Moderate Buy$50.11128.04% UpsideHSKAHeska 0.00N/AN/AN/ALNTHLantheus 3.00Buy$130.5064.75% UpsideMYGNMyriad Genetics 2.13Hold$14.38156.87% UpsideRIOTRiot Platforms 3.09Buy$17.3542.58% UpsideCurrent Analyst Ratings BreakdownLatest MYGN, HSKA, RIOT, LNTH, and CLDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025LNTHLantheusB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$122.00 ➝ $109.006/17/2025RIOTRiot PlatformsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $15.006/13/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.006/13/2025RIOTRiot PlatformsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$13.00 ➝ $14.005/21/2025MYGNMyriad GeneticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeSector Outperform ➝ Sector Perform$20.00 ➝ $6.005/15/2025MYGNMyriad GeneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$12.50 ➝ $9.005/9/2025CLDXCelldex TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$44.00 ➝ $38.005/9/2025CLDXCelldex TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$36.00 ➝ $31.005/9/2025CLDXCelldex TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$46.00 ➝ $43.005/8/2025LNTHLantheusTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$127.00 ➝ $117.005/8/2025MYGNMyriad GeneticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Peer Perform(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLDXCelldex Therapeutics$7.02M207.79N/AN/A$11.26 per share1.95HSKAHeska$257.31M5.09$1.69 per share70.99$39.00 per share3.08LNTHLantheus$1.53B3.57$6.99 per share11.34$15.65 per share5.06MYGNMyriad Genetics$837.60M0.62$1.00 per share5.60$7.70 per share0.73RIOTRiot Platforms$376.66M11.54$0.93 per share13.02$9.14 per share1.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLDXCelldex Therapeutics-$157.86M-$2.70N/AN/AN/A-2,366.07%-23.46%-22.35%8/6/2025 (Estimated)HSKAHeska-$19.89M-$1.93N/A83.33N/A-7.86%0.94%0.67%N/ALNTHLantheus$312.44M$3.5222.5012.55N/A16.55%36.99%20.55%7/30/2025 (Estimated)MYGNMyriad Genetics-$127.30M-$1.12N/AN/AN/A-12.20%-4.95%-3.39%8/5/2025 (Estimated)RIOTRiot Platforms$109.40M-$1.32N/AN/AN/A-86.93%-13.97%-11.99%7/30/2025 (Estimated)Latest MYGN, HSKA, RIOT, LNTH, and CLDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025LNTHLantheus$1.65N/AN/AN/A$389.69 millionN/A7/30/2025Q2 2025RIOTRiot Platforms-$0.27N/AN/AN/A$146.66 millionN/A5/8/2025Q1 2025CLDXCelldex Therapeutics-$0.75-$0.81-$0.06-$0.81$1.08 million$0.70 million5/7/2025Q1 2025LNTHLantheus$1.64$1.53-$0.11$1.02$377.37 million$372.76 million5/6/2025Q1 2025MYGNMyriad Genetics-$0.05-$0.03+$0.02N/A$200.37 million$195.90 million5/1/2025Q1 2025RIOTRiot Platforms-$0.25-$0.90-$0.65-$0.90$159.60 million$161.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLDXCelldex TherapeuticsN/AN/AN/AN/AN/AHSKAHeskaN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/AMYGNMyriad GeneticsN/AN/AN/AN/AN/ARIOTRiot PlatformsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLDXCelldex TherapeuticsN/A21.6721.67HSKAHeska0.235.644.12LNTHLantheus0.495.745.46MYGNMyriad Genetics0.081.901.71RIOTRiot Platforms0.203.233.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLDXCelldex TherapeuticsN/AHSKAHeska99.01%LNTHLantheus99.06%MYGNMyriad Genetics99.02%RIOTRiot Platforms40.27%Insider OwnershipCompanyInsider OwnershipCLDXCelldex Therapeutics4.40%HSKAHeska12.30%LNTHLantheus1.50%MYGNMyriad Genetics2.40%RIOTRiot Platforms6.93%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLDXCelldex Therapeutics15066.38 million63.46 millionOptionableHSKAHeska80810.91 million9.57 millionNot OptionableLNTHLantheus70069.19 million68.15 millionOptionableMYGNMyriad Genetics2,70092.18 million89.97 millionOptionableRIOTRiot Platforms340357.26 million332.51 millionOptionableMYGN, HSKA, RIOT, LNTH, and CLDX HeadlinesRecent News About These CompaniesElliott Wave Technical Analysis Riot Platforms, Inc. July 4 at 8:05 AM | talkmarkets.comRiot Ramps Up Crypto Mining Efficiency, Slashes Power Costs In June: Retail Stays BullishJuly 3 at 4:04 PM | msn.comRiot Announces June 2025 Production and Operations UpdatesJuly 3 at 9:00 AM | globenewswire.comRIOT Stock Reiterated to Outperform With 1.7 GW Data Center Pipeline and AI FocusJuly 2 at 10:35 PM | msn.comAI Is Quietly Transforming the Crypto Infrastructure While Most Eyes Chase HypeJune 28, 2025 | thecurrencyanalytics.comTRiot Platforms Inc Chart - MorningstarJune 28, 2025 | morningstar.comMRiot opens betting sponsorships for League of Legends and VALORANT teams in the Americas and EMEAJune 27, 2025 | gosugamers.netGRiot will let gambling companies sponsor League Of Legends and Valorant esports teamsJune 27, 2025 | rockpapershotgun.comRRiot Will Allow Sports-Betting Sponsorships For League Of Legends Esports TeamsJune 27, 2025 | gamespot.comGRiot turns to sports betting to help fund its esports leaguesJune 27, 2025 | theverge.comTRiot To Allow Gambling Sponsors in Esports, Says 'Betting Activity Already Exists'June 27, 2025 | msn.comRiot Games Greenlights Betting Sponsors for Tier 1 League of Legends and VALORANT TeamsJune 27, 2025 | msn.comRiot decides that allowing sports betting sponsorships in top-tier League of Legends and Valorant esports is a good ideaJune 27, 2025 | msn.comRiot Games Cancels Hytale, Shuts Down Hypixel Studios After Decade-Long DevelopmentJune 26, 2025 | msn.comRiot Platforms' Diversification Plan May Face Immense CompetitionJune 26, 2025 | seekingalpha.comRiot Platforms Inc Sustainability - MorningstarJune 25, 2025 | morningstar.comM3 Blockchain Stocks to Profit in a Decentralized World...June 24, 2025 | marketbeat.comRiot Platforms Unusual Options Activity For June 23June 23, 2025 | benzinga.com13 Crypto Stocks with the Highest Upside PotentialJune 20, 2025 | insidermonkey.comNeedham Lifts Price Target on Riot Platforms (NASDAQ:RIOT) to $15, Keeps a Buy RatingJune 20, 2025 | msn.com3 Crypto Stocks Surging as Stablecoin Bill Clears SenateJune 18, 2025 | schaeffersresearch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack Mode3 Blockchain Stocks to Profit in a Decentralized WorldBy Chris Markoch | June 24, 2025View 3 Blockchain Stocks to Profit in a Decentralized WorldMYGN, HSKA, RIOT, LNTH, and CLDX Company DescriptionsCelldex Therapeutics NASDAQ:CLDX$21.98 -0.14 (-0.61%) Closing price 07/3/2025 02:41 PM EasternExtended Trading$21.28 -0.70 (-3.16%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Heska NASDAQ:HSKAHeska Corporation manufactures and sells diagnostic and specialty products and solutions for veterinary practitioners in the United States, Canada, Mexico, Germany, Italy, Spain, France, Switzerland, Australia, and Malaysia. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell, platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was incorporated in 1988 and is based in Loveland, Colorado.Lantheus NASDAQ:LNTH$79.21 -0.41 (-0.51%) Closing price 07/3/2025 03:33 PM EasternExtended Trading$79.21 0.00 (0.00%) As of 07/3/2025 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Myriad Genetics NASDAQ:MYGN$5.60 -0.03 (-0.53%) Closing price 07/3/2025 02:38 PM EasternExtended Trading$5.60 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.Riot Platforms NASDAQ:RIOT$12.17 -0.03 (-0.25%) Closing price 07/3/2025 03:59 PM EasternExtended Trading$12.18 +0.01 (+0.10%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Riot Platforms, Inc., together with its subsidiaries, operates as a bitcoin mining company in North America. The company operates through three segments: Bitcoin Mining, Data Center Hosting, and Engineering. It also provides co-location services for institutional-scale bitcoin mining companies; critical infrastructure and workforce for institutional-scale miners to deploy and operate their miners; operation of data centers; and maintenance/management of computing capacity. In addition, the company engages in the design and manufacturing of power distribution equipment and custom engineered electrical products; and electricity distribution product design, manufacture, and installation services primarily focused on large-scale commercial, and governmental customers, as well as a range of markets, including data center, power generation, utility, water, industrial, and alternative energy. The company was formerly known as Riot Blockchain, Inc. Riot Platforms, Inc. was incorporated in 1998 and is based in Castle Rock, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
